Post-earnings recap
Reported
Fri, May 14, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
ImmunityBio's earnings report showed a significant beat on EPS, which likely contributed to the positive stock reaction, rising 4.63%. The company did not provide revenue figures or future guidance, leaving investors to focus on the EPS performance and management's optimistic tone regarding clinical advancements.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +48.78% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to ongoing clinical development.
We are pleased with our progress in the quarter.
Our focus remains on advancing our clinical programs.